CJC-1295 in Vicofertile — GHRH Analog Research Guide
CJC-1295 research guide for Vicofertile. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Vicofertile looking to source CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. This matters because CJC-1295 quality differs enormously across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor determines everything about the product. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. This guide takes Vicofertile researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Vicofertile researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Assessing CJC-1295 vendors begins with the COA: request the batch-specific certificate before purchasing, not after. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. Community reputation in research forums is a complementary signal to COA verification — vendors with consistently positive reports over 12+ months have built their reputation on real product performance. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Vicofertile
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and small-scale human observations. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bac water. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
